ArticleBJU international2026
Ex vivo fluorescence confocal microscopy for assessment of ureteroscopic biopsy adequacy in upper tract urothelial carcinoma.
Article in BJU international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the feasibility of ex vivo fluorescence confocal microscopy (FCM) for real-time assessment of ureteroscopic biopsy specimen adequacy in patients with suspected upper tract urothelial carcinoma (UTUC). PATIENTS AND
methodsIn this prospective, single-centre feasibility study, four ureteroscopic biopsy specimens obtained from two patients undergoing evaluation for suspected UTUC were analysed using ex vivo FCM. Specimens were briefly stained with acridine orange, scanned within 50-60 s, and images were stored for deferred review. A board-certified genitourinary pathologist reviewed the FCM images in a blinded fashion and classified specimens as adequate or non-representative based on a pre-defined criterion of identifiable urothelial tissue. All specimens subsequently underwent routine haematoxylin and eosin (H&E) histopathological analysis for confirmation.
resultsEx vivo FCM was successfully performed on all specimens without workflow interruption, with total preparation and image acquisition completed within approximately 5 min/specimen. Blinded FCM review identified urothelial tissue in three of four biopsy specimens, which were classified as adequate, while one specimen was composed predominantly of blood clot with only minimal, non-diagnostic cellular material and was therefore classified as non-representative. FCM-based adequacy assessments were concordant with corresponding H&E sections. Final histopathology demonstrated non-invasive papillary UC, high grade in one patient and low grade in the other; the non-representative specimen showed only focal atypical papillary urothelial proliferation admixed within the blood clot.
conclusionEx vivo FCM was feasible for immediate imaging of freshly obtained ureteroscopic biopsy specimens and allowed identification of urothelial-containing fragments as a marker of specimen adequacy while preserving tissue for standard histopathological evaluation. These preliminary findings support further investigation in larger cohorts to evaluate reproducibility and to clarify the potential role of this approach for intraoperative or real-time assessment of biopsy adequacy in UTUC, including correlation with final histopathological grade and stage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.